Lightera Advances Fiber-integrated Temperature Feedback for Safer Laser-based Medical Procedures 
GridAI: The Grid Is the New Battleground for AI Economics
BOCA RATON, FL / ACCESS Newswire / January 12, 2026 / For years, investors were trained to believe the bottleneck...
GridAI: The Grid Is the New Battleground for AI Economics
BOCA RATON, FL / ACCESS Newswire / January 12, 2026 / For years, investors were trained to believe the bottleneck...
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP...
Black Book Research Releases 2026 State of South Korean Acute Care EMR Digital Adoption Report
Strategic Fit Assessment Finds Leadership Concentrated in Enterprise-Scale Clinical Performance and Resilience While Cloud Agility, Partnership Value, and Patient Engagement...
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire /...
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE...
Mixie Technologies, Inc. (PHCG) Announces CES Picks Award Recognition for HoloTwin LLC
Recognition by TechRadar Pro at CES 2026 underscores the strategic rationale behind Mixie’s strategic investment in HoloTwin’s AI-driven digital twin...
HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. Morgan Healthcare Conference
DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health...
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026...
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal...
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib...
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential-...
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and...
Counterpart Health 2025 Results: How Better Clinical Decisions at Scale Improve Outcomes, Quality, and Cost
Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and...
Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026
Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million...
Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
– Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of...
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12,...
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the...
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional...